Pharmaids posted a ₹1.81 crore net loss in Q2 FY27, reversing a profitable Q1 that was propped up by a one-off gain, while revenue fell nearly 50% year-on-year.
Pharmaids Pharmaceuticals' Q2 FY27 saw revenue drop 49.6% year-on-year to ₹4.34 crore. The company swung to a net loss of ₹1.81 crore, erasing the prior quarter's profit which was driven by a ₹4.2 crore exceptional gain.
For a company in the midst of a business transition, quarterly results can be volatile. Pharmaids Pharmaceuticals' September quarter showed just how sharp those swings can be, as a one-off gain that delivered profit in June evaporated.
Revenue for Q2 FY27 was ₹4.34 crore, down 49.6% from the same period last year. The company posted a net loss of ₹1.81 crore, a reversal from the ₹1.87 crore profit reported in Q1. This pushed the trailing-twelve-month net profit margin to -17.4%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr)
Profit (₹ Cr)
| Metric | CurrentQ2 FY27 (Sep 2026) | PreviousQ1 FY27 (Jun 2026) |
|---|---|---|
| Revenue (₹ Cr) | 4.34 | 4.12 |
| Profit (₹ Cr) | -1.81 | 1.87 |
| PAT Margin (%) | -41.7 | 45.4 |
The stark quarter-on-quarter swing is explained by a non-recurring item. According to a MarketsMojo alert, the company's profit in the first half of FY27 was ₹0.06 crore, aided by a ₹4.2 crore exceptional gain in Q1. Without that boost, the underlying business continued to operate at a loss.
Total expenses rose 13.7% sequentially to ₹6.77 crore, even as revenue inched up only 5.3%. Interest costs increased 9.3% to ₹0.66 crore, reflecting the company's debt load.
The operational challenges are mirrored in the balance sheet. Consolidated borrowings rose to ₹25.50 crore as of September 30, 2026, from ₹22.24 crore at the end of March, as reported by Multibagg.ai. The current ratio stands at 0.77, indicating tight liquidity.
Live Chart
· PHARMAID
(BSE)
ISIN: INE117D01018
Net cash generated from operations was a minimal ₹1.89 lakh for the half-year. With no FII or DII ownership, as noted by StockFin.ai, the company lacks institutional investor support.
The stock showed no immediate reaction, closing at ₹29.17 on the results date. It has declined 34.3% over the past year.
Key Points
The quarter underscores the fragility of Pharmaids' ongoing transition. The core business, excluding one-time gains, is not yet profitable, and revenue remains a fraction of its level from a year ago.
Investors are weighing a business that is burning cash against a debt pile that is still growing. The path to sustainable profitability depends on securing steady contract research and manufacturing service (CRAMS) revenue, for which there is little visibility in these consolidated numbers. Until that revenue base is established, volatility between quarters is likely to remain the norm.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.